menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Hengrui Medicine"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ MD Anderson","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yingli Pharmaceutical \/ MD Anderson"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TEB-17231","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"YL-17231","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"280Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Yingli Pharmaceutical

    Menu

    Shanghai Yingli Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            280Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            280Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YL-17231

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            280 Bio Receives IND Approval from the FDA for YL-17231

                            Details : YL-17231 has a broader activity than many current KRAS inhibitors and demonstrated strong inhibition of in vivo KRAS mutant xenograft tumor growth in our preclinical investigations.

                            Brand Name : YL-17231

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 07, 2023

                            Lead Product(s) : YL-17231

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TEB-17231

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

                            Details : TEB-17231 is a KRAS Inhibitor, it has shown robust tumor growth inhibition, against KRASG12V, KRASG12C, KRASG12D and other RAS mutant tumor cell lines. It is in preparation for phase1 studies for the treatment of KRAS-mutated cancer patients.

                            Brand Name : TEB-17231

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2023

                            Lead Product(s) : TEB-17231

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma

                            Details : Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical develo...

                            Brand Name : YY-20394

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2022

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MD Anderson and Yingli Pharma Initiate Strategic Collaboration to Advance Development of Multiple Oncology Pro...

                            Details : The collaborative approach will provide a steady stream of therapeutic candidates, YL-13027, for oncology clinical development, which the MD Anderson team, including David S. Hong, M.D., deputy chair of Investigational Cancer Therapeutics, will investiga...

                            Brand Name : YY-20394

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 20, 2022

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Yingli Pharma to Present on the Phase 2 Clinical Trial of Linperlisib

                            Details : Linperlisib, a potent oral PI3Kδ inhibitor, had robust clinical activity with 79.5% ORR in relapsed or refractory Follicular Lymphoma. The safety data from the FL Phase 2 study indicated that linperlisib was generally safe and tolerable with manageable ...

                            Brand Name : YY-20394

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2021

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Shanghai Yingli Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : $20.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China

                            Details : Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.

                            Brand Name : YY-20394

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2021

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : $20.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth